Where is Edwards Lifesciences headquarters?
Edwards Lifesciences Corporation has its global corporate headquarters located at One Edwards Way in Irvine, California. Situated within the master-planned business community of the Irvine Spectrum area in Orange County, this expansive campus houses the company's executive administration, global research laboratories, advanced engineering spaces, and manufacturing facilities. The headquarters directs the enterprise's pioneering development of structural heart disease treatments and critical care monitoring technologies.
Related FAQs
Edwards Lifesciences operates as a global leader in patient-focused medical innovations for structural heart disease, exposing shareholders to unique healthcare sector risks.
Edwards Lifesciences (EW) currently presents mixed signals for investors. As of July 2026, it holds a "Hold" rating from AI-driven analysis models, which suggest only a limited probability of outperforming the market in the near term.
Edwards Lifesciences (EW) is frequently categorized as a growth-oriented company in the medical technology sector, particularly known for its focus on innovation in structural heart disease and critical care monitoring.
Vice presidents managing automation solutions, commercial and residential climate technologies, industrial software, or global manufacturing operations at Emerson Electric earn advanced executive salaries.
Market analysis as of late July 2026 characterizes Edwards Lifesciences (EW) as a "Hold" rather than a clear "Buy".
An exchange functions as a centralized or electronic marketplace where buyers and sellers come together to trade financial instruments, commodities, or services under standardized rules and regulations.
Yes, Edwards Lifesciences is often evaluated through the lens of its growth potential, particularly in the medical technology space, where it is known for products like transcatheter aortic valve replacement (TAVR).
Small Business Administration loans are formal debt financing instruments that must be fully repaid in accordance with strict contractual terms, interest rates, and amortization schedules.
Edwards Lifesciences Corporation (EW) is a global leader in patient-focused medical innovations for structural heart disease, specializing in advanced transcatheter aortic valve replacement (TAVR) technologies.
Equity research analysts covering Edwards Lifesciences Corporation (EW) maintain a consensus average twelve-month price target of approximately $100.96 per share.
The three-five-seven rule in stock market trading represents a risk management framework and technical heuristic used by active traders to establish structured profit targets, stop-loss boundaries, and scaling strategies.
Penny stocks and out-of-the-money equity options represent the riskiest types of stock investments.
Edwards Lifesciences has been recognized in various corporate rankings; for instance, it was ranked 89th overall in the 2022 Top 100 ESG Companies list by ESG Book.
Enterprises or medical technology leaders associated with the Edwards designation look toward an innovative future driven by advanced structural heart disease treatments, transcatheter aortic valve replacement systems, and surgical heart valve innova...
Yes, Exchange Bank provides its customers with access to Zelle, which is integrated directly into its mobile banking application.
Edwards Lifesciences Corporation holds exceptional long-term prospects as a global pioneer and structural heart innovation leader, specializing in transcatheter aortic valve replacement and advanced surgical heart valve technologies.
Financial analysts and macroeconomic forecasters generally project a cautiously optimistic ten-year outlook for the global stock market, driven by secular growth trends in artificial intelligence, cloud computing, automation, and green energy transit...
Wall Street equity research analysts covering Edwards Lifesciences Corporation (EW) establish a consensus 12-month average price target of approximately $101.17 to $101.78 per share.
EW is the ticker symbol for Edwards Lifesciences Corp., a major medical technology company specializing in patient-focused innovations for structural heart disease and critical care monitoring.